SENSEX NIFTY
Torrent Pharmaceuticals > Company History > Pharmaceuticals > Company History of Torrent Pharmaceuticals - BSE: 500420, NSE: TORNTPHARM
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Torrent Pharmaceuticals
Torrent Pharmaceuticals
BSE: 500420|NSE: TORNTPHARM|ISIN: INE685A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Sep 18, 17:00
844.70
-10.3 (-1.2%)
VOLUME 34,255
LIVE
NSE
Sep 18, 17:00
839.65
-16.05 (-1.88%)
VOLUME 191,668
Company History - Torrent Pharmaceuticals
1972 - The Company was incorporated on 15th July, as a Private Limited
 Company by Shri Rajnikant C. Patel and his family members, and in June
 1982, the company was acquired by Shri Uttamlal N. Mehta. 
 
 - The Company is primarily engaged in the manufacture of various
 Pharmaceuticals formulations and bulk drugs.  The products of the
 Company enjoy good reputation and are well accepted in the market. 
 
 - The Company has taken up manufacture of bulk drugs as a strategic
 value added backward integration to its formulation activities.
 
 1989 - On 28th June the Company became a deemed Public Company under
 the provisions of Section 43-A of the Act and by a Special Resolution
 passed on 25th July, 1992 at the Annual General Meeting, the Company
 became a Public Limited Company within the meaning of Section
 3(1)(iv) of the act and adopted a new set of articles.
 
 1992 - Torrent Laboratories Limited, was amalgamated with the Company
 with effect from 1st April by an order of the Honourable High Court of
 Gujarat, dated 22nd December.
 
 - The Company proposes to undertake an expansion-cum modernisation of
 its existing facilities, setting up facilities for manufacture of new
 products apart from setting up a separate in-house Research &
 Development Centre.
 
 - The Company further broad base its product range through in-house
 manufacture of Ranitidine HCL, Diltiazem, HCL and Atenolol with an
 installed capacity of 12 tpa each.
 
 - The company proposes to set-up in-house production facilities for
 Large Volume Parentrals with an installed capacity of 14.5 million
 bottles p.a. for better quality control and for diversifying the
 product range to include dextrose/saline injectibles and value added
 items like fluconazole infusion. 
 
 1993 - The Company proposes to modernize its present manufacturing
 facilities located at Vatva and Chhatral to conform to the GMP
 requirements as also to incorporate the latest technology available
 in the field.
 
 - During the year, Torrent Medi-Systems Limited (TMSL) was merged
 with the Company with effect from 1st April consequent to the scheme
 of amalgamation approved by the Honourable High Court of Gujarat. 
 
 - The Company proposes to install 2 nos. 100 cfm air compressors to
 meet the additional requirement of compressed air.
 
 - The Company has issued 12,88,400 No. of Equity shares of Rs 10 each
 as fully paid bonus shares to the shareholders in the ratio of one
 share for every one share held by them on 7 August.
 
 - The Company has issued 1,25,49,056 No. of Equity shares of Rs 10
 each as fully paid bonus Shares to the shareholders in the ratio of
 487 shares for every 100 shares held by them on 12 November. 
 
 1994 - The Company issued 1,74,144 Equity Shares of Rs.10 each as
 fully paid up shares to the shareholders of TMSL after cancelling
 9,300 Shares held by the Company in TMSL.
 
 - The Company was the first to launch ranitidine (Ranitin),
 nifedipine (Calcigard,) atenolol (Betacard), domperidone (Domstal),
 diltiazem (Dilzem), amiodorane (Cordarone), Lisinopril (Listril),
 etc. in the Indian market.
 
 - The Company is a leader in the Cardiovascular segment with a number
 of brand leaders in its product portfolio like Dilzem, Cordarone,
 Listril, etc.
 
 - Torrent occupies the third position in the industry in
 Gastro-Intestinal Drugs segment with well established products like
 Ranitin, Topcid, Domstal, Omizac, etc.
 
 - During the year the Company launched a number of new products like
 Zirtin, Tyklid, Flutamide and Topcef, all of which were well received
 in the market place.
 
 - The Company has created specialized `Disease Management Groups' top
 strengthen promotion of Psychotropic and Cardiovascular products. 
 
 - During the year manufacturing of several other new bulk drugs was
 also undertaken like Norfloxacin, Ciprofloxacin, Ranitidine,
 Atenolol, Diltiazem, etc.
 
 - The Company is considering technical tie-ups with Indian and
 Foreign research institutes for new molecules in the chemical and
 biotechnology spheres and for pharmacological screening of new
 compounds.
 
 1995 - During the year the Company launched a number of new products
 like Lomef (Lomefloxacin), Dilzem Inj. (Diltiazem), Depidol LA
 (Haliiperidiil Decanoate) Oncoden (Ondancetron), Nimotide
 (Nimodipne), Pefcin (Pefloxacin) which have gained wide acceptance in
 the pharmaceutical market.
 
 - The Company proposes to introduce OA/GYN and General Purpose
 Radiology with a new marketing tie-up with Dynamic Imaging of UK.
 
 - The Company proposes to launch new molecules to strengthen its
 product portfolio and to consolidate leadership in the relevant
 therapeutic segments.
 
 - The Company has entered into a strategic alliance with Pfizer Inc.
 USA the fourth largest pharmaceutical company in the world.
 
 1996 - During the year, your company introduced six new drugs,
 Lozapin, a drug of therapeutic choice to treat resistant
 Schizophrenia, was made available for the first time in the country. 
 All the six new drug introductions, comprising, Licab XL, IV Metro,
 Vasotrate, Clonotril and Teralfa were received enthusiastically by
 the medical fraternity.
 
 - During the year, it has also set up a state-of-the-art information
 management system.
 
 - The company introduced Lamitor (Lamotrigine) an advanced
 anti-epileptic, Serenata (Sertraline) - an anti-depressant - and
 Tozar (Losartan), an anti hypertensive under a new class of molecules
 called Angiotensin II inhibitors.  It also launched Syscan
 (flucanozole) eye
 drops for the treatment of ophthalmic fungal infections. 
 
 1997 - The company has strategic alliances with world-renowned
 pharmaceutical giants like Sanofi, France, for cardio-vascular
 produces; and Novo Nordisk, Denmark, in the area of diabetic care. 
 
 - Torrent has become one of the largest exporters of medical
 formulations from India, with sales in over 70 countries and a
 network of overseas marketing offices.
 
 - Torrent Pharmaceuticals Limited, a pharmaceutical company belonging
 to Torrent Group, has entered into an agreement with Sanofi Pharma of
 France, to launch a 50:50 joint venture company, Sanofi Torrent India
 to develop the Indian and global pharmaceutical industry.
 
 1998 - Other new products introduced in the market include Normabrain
 800 and Amlocar which have been well received by the medical
 fraternity.  The company's drug Lozapin for the treatment of
 resistant schizophrenia also is amongst the first time launch in the
 country. 
 
 - The Mehtas-controlled Torrent Pharmaceuticals Ltd is seeking
 tie-ups for molecular research in therapeutic segments such as
 anti-infectives, cardio-vascular and neuropsuchiatry.
 
 - The company has a tie-up with the Denmar-based Novo Nordisk to
 manufacture and market insulin and a venture with the French firm,
 Sanofi.
 
 1999 - Among the new products launched recently included Nikoran IV
 for critical care in cardiology and a novel drug approved for launch
 in the anti-epileptic category.
 
 2000 - Torrent Pharmaceuticals covers various therapeutic groups such
 as cardiovascular formulations, psychotropic formulations and
 gastro-intestinal drugs.  Apart from this, the company has a marginal
 presence in the bulk drugs segment.  It has tie-ups with various
 international majors.
 
 - The flagship company TPL has undertaken a major restructuring.
 exercise by creating three distinct divisions to give focus on mega
 brands, super speciality and sub-speciality products respectively. 
 
 - The Company has launched a new product Eurepa (repaglinide) with a
 therapeutic profile suited to Indian type-II diabetic patients. 
 
 2001 
 
 - The Company has launched all over the country an oral anti
 impotence drug `Androz' (sidenafil nitrate).
 
 - The Company has launched De Platt (clopidogrel) the drug of choice
 for treating heart attack and stroke.
 
 2002
 
 -Torrent Pharmaceuticals has launched leflunomide - a new generation
 rheumatoid arthritis drug, at a big discount to its innovator,
 multinational Aventis Pharma.
 
 -Torrent Pharma’s manufacturing facilities certified with ISO
 14001:1996. 
 
 -Torrent’s R&D Centre received ISO/IEC 17025:1999 for its facilities
 by National Accreditation Board for Testing and Calibration
 Laboratories (NABL).
 
 2003
 
 -Torrent Pharma sets up a wholly owned subsidiaries in Germany and
 Brazil.
 
 -Torrent Pharma launches 'Aripiprazole' new antiseptic drug under the
 Brand name
 of Arip MT.
 
 -a) New API manufacturing plant for catering to regulated markets;
 (b) New formulations facilities at one or more locations for catering
 to regulated markets & meeting the anticipated growth in the domestic
 market. ii) Incorporate a wholly owned subsidiary in USA. 
 
 -Torrent unveils COX 2 variants
 -IDMA Quality Excellence Award Gold Trophy for its formulations and
 API facilities.
 
 2004
 
 -Torrent Pharma  launches Ecogat
 
 -Torrent Pharmaceuticals Ltd, in association with State Mental Health
 Authority, Health and family Welfare Department, launches 'Sanidhya -
 Torrent Medical Healthline' in Bhat near Gandhinagar in Gujarat
 
 -Torrent, the Indian pharmaceutical major, announced the launch of
 Rozucor - the New Super Statin in Karnataka.
 
 -Torrent Pharmaceuticals Limited (TPL) has signed a non-exclusive
 agreement with Dr. Reddy's Laboratories Limited (DRL) for licensing
 and supplying the formulation of one of Torrent's blockbuster drug
 'Domstal O' in the Gastro Intestinal segment
 
 -Torrent Pharmaceuticals Ltd has launched Etoricoxib, the new
 generation anti-arthritic drug under the brand name Torcoxia
 
 -Launches Duloxetine, a new-age anti-depressant under the brand name
 `Symbal'.
 
 2005
 
 -Torrent Pharmaceuticals Ltd launches a new anti-epileptic drug
 Levetiracetam
 
 -Torrent acquires Pfizer generic subsidiary in Germany
 
 -Torrent Pharmaceuticals signs agreement with Novo Nordisk, Denmark
 to establish new, dedicated formulation and packaging facility for
 Insulin, exclusively for Novo Nordisk
 
 2006
 
 -Torrent Pharma Receives USFDA Approval
 
 -Torrent’s Azuca launches 2 new blockbusters, Pregeb and Piopod
 
 -Entered into an in-licensing deal with Tasly of China to market its
 Cardiotonic pill in India
 
 -Torrent Pharmaceuticals Ltd has announced that the Company has
 launched Nexpro Fast (Immediate Release Esomeprazole), a Proton Pump
 Inhibitor (PPI), for the first time in India to treat peptic ulcers
 and GERD (Gastro Esophageal Reflux Disease). 
 
 -The API and formulations manufacturing facilities located at Indrad
 (Gujarat, India) got US FDA approval 
 
 -Torrent Pharma launches AzuCa, its super-specialty Diabetes
 division
 
 -Torrent Pharmaceuticals has given the Bonus in the Ratio of 1:1
 
 -Company has splits its Face value of Shares from Rs 10 to Rs 5
 
 2007
 
 - Torrent unveils laxative in tablet form
 
 -Torrent Pharma launches CVpill, The world’s first ‘polypill’ in
 Cardiac care
  
 -Indians to get slimmer and fitter: Torrent Pharma launches Rimoslim;
 India’s first Rimonabant
  
 -Torrent Pharma launches Fibotab; India’s first bulk laxative in
 tablet form
 
 2009
 
 -Torrent’s New Insulin Facility to produce 26 million vials pa for
 Novo Nordisk
 
 2010
 
 - The Board  has recommended a dividend of Rs. 6.00 per equity share
 having face value of Rs. 5/- each.
 
 2011
 
 - Torrent Pharma gets US FDA approval for alfuzosin hydrochloride
 extended release tablets.
 
 - Board have recommended a normal annual dividend of Rs. 6 per equity
 share of Rs. 5/- each and a special dividend of Rs. 2.00 per equity
 share of Rs. 5/ each fully paid up.
 
 2012
 
 - The Board has appointed Haigreve khaitan as Additional Director.
 
 - The Board has recommended a final dividend of Rs. 2.50 per equity
 share.
Source : Dion Global Solutions Limited
Quick Links for Torrent Pharmaceuticals
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.